<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386839</url>
  </required_header>
  <id_info>
    <org_study_id>SHP607-201</org_study_id>
    <secondary_id>2014-003556-31</secondary_id>
    <nct_id>NCT02386839</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROP-2008-01 for the Prevention of ROP</brief_title>
  <acronym>PEDAL</acronym>
  <official_title>Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated With rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study will compare safety and efficacy treatment outcomes in infants that
      received study drug treatment with infants that received standard neonatal care in Study
      ROPP-2008-01 (NCT01096784).
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of Retinopathy of Prematurity (ROP) as compared to the severity of ROP in an untreated control population.</measure>
    <time_frame>At 5.5 years corrected age (CA)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event- Physical examination including tonsil examination, cardiac size (echocardiogram), kidney and spleen size, and any other gross abnormalities (abdominal ultrasound), and concomitant medications/procedures</measure>
    <time_frame>Baseline to 5.5 years (CA)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual acuity as assessed by an age-appropriate method</measure>
    <time_frame>6 months to 5.5 years (CA)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Corrective lens determination as assessed by standard guidelines published by the AAO</measure>
    <time_frame>12 months to 5 years (CA)</time_frame>
    <description>American Academy of Ophthalmology (AAO)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular alignment and ocular motor examination in primary gaze and in as many of 9 positions of gaze as possible as assessed by corneal light reflex and by the cover test</measure>
    <time_frame>12 months to 5.5 years (CA)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Refraction as assessed by retinoscopy with cycloplegia</measure>
    <time_frame>6 months to 5.5 years (CA)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stereoacuity as assessed with standardized, age-appropriate tools</measure>
    <time_frame>At 5.5 years (CA)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal layer and optic nerve development as assessed by optical coherence tomography (OCT)</measure>
    <time_frame>At 5.5 years (CA)</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Retinopathy of Prematurity (ROP)</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Short-term exposure to rhIGF-I/rhIGFBP-3 in previous study ROPP-2008-01 (NCT# 101096784)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Standard neonatal care in previous study ROPP-2008-01(NCT# 101096784)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mecasermin rinfabate</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>rhIGF-I/rhIGFBP-3</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects randomized in Study ROPP-2008-01, Section D are eligible to enroll in this study;
        completion of Study ROPP-2008-01 Section D is not required. Subjects in Study ROPP-2008-01
        are premature infants (gestational age of 23 weeks + 0 days to 27 weeks + 6 days) who are
        randomized to receive either treatment with rhIGF-1/rhIGFBP-3 or standard neonatal care. Up
        to 120 subjects are planned to be randomized in Study ROPP-2008-01 Section D.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject was randomized in Study ROPP-2008-01, Section D

          2. Subject's parent or legally authorized representative(s) must provide written informed
             consent prior to performing any study-related activities. Study-related activities are
             any procedures that would not have been performed during normal management of the
             subject.

        Exclusion Criteria:

          1. Any other condition or therapy that, in the Investigator's opinion, may pose a risk to
             the subject or interfere with the subject's ability to be compliant with this protocol
             or interfere with the interpretation of results

          2. The subject or subject's parent or legally authorized representative(s) is unable to
             comply with the protocol as determined by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Weeks</minimum_age>
    <maximum_age>52 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama Children's and Women's Hospital</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Mercy Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vidant Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini-Istituto Pediatrico di Ricovero e</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padua</name>
      <address>
        <city>Padua</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>﻿00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ginekologiczno-Położniczy Szpital Kliniczny Uniwersytetu Medycznego w Poznan</name>
      <address>
        <city>Poznań</city>
        <zip>60-535</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skanes Universitetssjukhus Lund</name>
      <address>
        <city>Lund</city>
        <zip>SE-22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Peter's Hospital</name>
      <address>
        <city>Chertsey</city>
        <zip>KT16 0PZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Childrens Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L8 7SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL EGA Institute for Women's Health</name>
      <address>
        <city>London</city>
        <zip>WC1E 6AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mecasermin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

